Cerebral palsy · preterm infants with chronic lung disease
Systemic corticosteroids (dexamethasone or hydrocortisone) showed no clear difference in cerebral palsy ‐ at latest reported age compared with control (placebo or nothing) (high certainty).
1 finding from 1 review
Death or cerebral palsy · preterm infants with chronic lung disease
Systemic corticosteroids (dexamethasone or hydrocortisone) showed no clear difference in mortality or cerebral palsy ‐ at latest reported age compared with control (placebo or nothing) (high certainty).
1 finding from 1 review
Mortality Mortality at latest · preventing bronchopulmonary dysplasia in preterm infants
Early systemic postnatal corticosteroids showed no clear difference in mortality at latest reported age compared with placebo or no treatment (high certainty).
1 finding from 1 review
BPD (36 weeks' PMA) · preventing bronchopulmonary dysplasia in preterm infants
Early systemic postnatal corticosteroids probably leads to lower BPD (36 weeks' PMA) compared with placebo or no treatment (moderate certainty).
1 finding from 1 review
Death or bronchopulmonary dysplasia at 36 weeks PMA · preventing bronchopulmonary dysplasia in preterm infants
Early systemic postnatal corticosteroids leads to lower mortality or BPD at 36 weeks' PMA compared with placebo or no treatment (high certainty).
1 finding from 1 review
Gastrointestinal perforation during primary hospitalisation · preventing bronchopulmonary dysplasia in preterm infants
Early systemic postnatal corticosteroids leads to higher gastrointestinal perforation during primary hospitalisation compared with placebo or no treatment (high certainty).
1 finding from 1 review
Cerebral palsy · preventing bronchopulmonary dysplasia in preterm infants
Early systemic postnatal corticosteroids leads to higher cerebral palsy at latest reported age compared with placebo or no treatment (high certainty).
1 finding from 1 review
Death or cerebral palsy · preventing bronchopulmonary dysplasia in preterm infants
Early systemic postnatal corticosteroids showed no clear difference in mortality or cerebral palsy at latest reported age compared with placebo or no treatment (high certainty).
1 finding from 1 review
50% or greater reduction in seizure frequency Number of seizures · people with drug‐resistant focal epilepsy
Gabapentin probably leads to higher reduction in seizure frequency of ≥ 50%: primary analysisNumber of… compared with placebo (moderate certainty).
1 finding from 1 review
Treatment withdrawalNumber of participants withdrawn for any reason · people with drug‐resistant focal epilepsy
Gabapentin showed no clear difference in treatment withdrawalNumber of participants withdrawn for any reason compared with placebo (moderate certainty).
1 finding from 1 review
Adverse effects: ataxia Number of participants experiencing ataxia · people with drug‐resistant focal epilepsy
Gabapentin may leads to higher adverse effects: ataxiaNumber of participants experiencing ataxia compared with placebo (low certainty).
1 finding from 1 review
Frequency of adverse effects ‐ dizziness ( · people with drug‐resistant focal epilepsy
Gabapentin probably leads to higher adverse effects: dizzinessNumber of participants experiencing… compared with placebo (moderate certainty).
1 finding from 1 review
Adverse effect: fatigue · people with drug‐resistant focal epilepsy
Gabapentin may leads to higher adverse effects: fatigueNumber of participants experiencing fatigue compared with placebo (low certainty).
1 finding from 1 review
Nausea · people with drug‐resistant focal epilepsy
Gabapentin probably leads to lower adverse effects: nauseaNumber of participants experiencing nausea compared with placebo (moderate certainty).
1 finding from 1 review
Somnolence · people with drug‐resistant focal epilepsy
Gabapentin probably leads to higher adverse effects: somnolenceNumber of participants experiencing… compared with placebo (moderate certainty).
1 finding from 1 review
Adverse effects: headache · people with drug‐resistant focal epilepsy
Gabapentin probably leads to lower adverse effects: headacheNumber of participants experiencing headache compared with placebo (moderate certainty).
1 finding from 1 review
Exacerbations: number of people experiencing moderate or severe exacerbations · treatment for asthma in adults and children with asthma and GORD
Medical or surgical intervention, or both, for gastro‐oesophageal… showed no clear difference in number of participants with moderate/severe acute exacerbations… compared with nil intervention, delayed intervention control, or placebo (low certainty).
1 finding from 1 review
Lung function: FEV1 mL (change from baseline) · treatment for asthma in adults and children with asthma and GORD
1 finding from 1 review
Use of "rescue" medications and emergency action plans: B2 use puffs per day Duration of treatment: range 14 weeks to 24 weeks · treatment for asthma in adults and children with asthma and GORD
1 finding from 1 review
Change in quality of life · treatment for asthma in adults and children with asthma and GORD
1 finding from 1 review